Research graph
References from PARAGON-II cohort C: a phase II basket study of letrozole plus ribociclib in hormone receptor–positive, platinum-resistant, high-grade epithelial ovarian cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Epithelial ovarian cancer
2026 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2023.07.011 · 2023 · External reference
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
10.1136/ijgc-2021-003142 · 2022 · External reference
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the Aurelia open-label randomized phase III trial
10.1200/jco.2013.51.4489 · 2014 · External reference
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
10.1016/s0140-6736(25)01040-2 · 2025 · External reference
Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer
10.1056/nejmoa2309169 · 2023 · External reference
Pembrolizumab VS placebo plus paclitaxel ± bevacizumab for platinum-resistant recurrent ovarian cancer: results from the PHASE 3 ENGOT-OV65/KEYNOTE-B96 study
10.1016/j.ijgc.2025.102732 · 2025 · External reference
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
10.1016/s1470-2045(13)70253-5 · 2013 · External reference
Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study
10.1080/0284186x.2018.1546061 · 2019 · External reference
Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature
10.1093/oncolo/oyae093 · 2024 · External reference
NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer
2026 · External reference
Paragon (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
10.3802/jgo.2019.30.e86 · 2019 · External reference
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
10.1038/bjc.2016.435 · 2017 · External reference
Cyclin D as a therapeutic target in cancer
10.1038/nrc3090 · 2011 · External reference
The Strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies
10.1016/j.trecan.2016.11.006 · 2017 · External reference
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer
10.1158/1078-0432.ccr-10-2307 · 2011 · External reference
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
10.1002/cjp2.109 · 2018 · External reference
Overall survival with ribociclib plus letrozole in advanced breast cancer
10.1056/nejmoa2114663 · 2022 · External reference
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
10.1016/s1470-2045(18)30292-4 · 2018 · External reference
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
10.1007/s11136-017-1729-8 · 2018 · External reference
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer
10.1016/j.ygyno.2024.02.025 · 2024 · External reference
A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018)
10.1016/j.ygyno.2025.05.022 · 2025 · External reference
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
10.1136/esmoopen-2020-000926 · 2020 · External reference
Phase II trial of ribociclib plus letrozole in women with recurrent low-grade serous carcinoma of the ovary, Fallopian tube, or peritoneum: a GOG partners trial (GOG 3026)
10.1200/jco-25-01348 · 2026 · External reference
Integrated genomic analyses of ovarian carcinoma
10.1038/nature10166 · 2011 · External reference
Whole–genome characterization of chemoresistant ovarian cancer
10.1038/nature14410 · 2015 · External reference
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: an Ovarian Tumor Tissue Analysis consortium study
10.1002/cncr.34582 · 2023 · External reference
Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication
10.1016/j.cell.2022.12.036 · 2023 · External reference
Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC)
10.1200/jco.2025.43.16_suppl.5514 · 2025 · External reference
Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers
10.18632/oncotarget.15858 · 2017 · External reference
